Ketorolac Abc (Ketorolac Trometamol)

Ketorolac trometamol blocks both COX‑1 and COX‑2 enzymes, which reduces the production of prostaglandins that mediate pain, inflammation, and fever. This inhibition leads to decreased peripheral sensitisation and provides analgesic and anti‑inflammatory effects.

The specific dose and duration are determined by the prescribing clinician based on the patient’s condition, weight, renal function, and procedural context. Ketorolac is typically limited to short‑term use, not exceeding five days.

Ketorolac is generally contraindicated in the third trimester of pregnancy because of the risk of fetal renal impairment and premature closure of the ductus arteriosus. Safety in earlier trimesters and during breastfeeding has not been fully established, so a risk‑benefit assessment is required.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and any required import documentation.

Ketorolac provides analgesia comparable to moderate‑dose opioids for short‑term use but without the risk of respiratory depression. Compared with other NSAIDs, it has a higher potency for pain relief but also a greater risk of renal and gastrointestinal adverse effects, especially when used beyond five days.

Ketorolac Abc injection should be stored at 2‑8 °C, protected from light, and kept in its original container. Do not freeze or shake the vial. If refrigeration is unavailable for a brief period, the product may be kept at controlled room temperature for up to 24 hours, but it should be returned to the refrigerator promptly.

Ketorolac Abc is administered by a healthcare professional via intramuscular or intravenous injection. The injection site should be cleaned with an appropriate antiseptic, and the dose is given slowly to minimise the risk of local irritation or systemic side effects.

The most serious risks include gastrointestinal bleeding or perforation, severe renal impairment, cardiovascular thrombotic events such as heart attack or stroke, and life‑threatening allergic reactions like anaphylaxis. Patients should be monitored closely for signs of these complications.

Ketorolac should be avoided in patients with known hypersensitivity to ketorolac or other NSAIDs, active gastrointestinal bleeding or ulcer disease, severe renal or hepatic impairment, uncontrolled hypertension, and in the third trimester of pregnancy. Caution is also advised for patients on anticoagulants or with a history of cardiovascular disease.